America’s dependency on the People’s Republic of China for our drug supply chain is a real problem. And the Trump administration has begun tackling it.
Seeking to secure the nation’s supply of critical medications, the Trump administration has signed a $354 million contract that would create the nation’s first strategic stockpile of key ingredients needed to make medicines.
The agreement was signed Monday with Phlow Corp., a generic drug maker based in Virginia. According to a news release to be made public Tuesday, the project will use federal funds from the Biomedical Advanced Research and Development Authority under the Department of Health and Human Services.
The goal is twofold: to enable the U.S. to manufacture essential drugs at risk of shortage and to create a reserve of active pharmaceutical ingredients to reduce the dependence on foreign suppliers.
Phlow’s CEO, Dr. Eric Edwards, told NBC News that the company had been in discussions with the administration back in November but that the project was fast-tracked once COVID-19 hit.
America needs to decouple from a CCP supply chain. And when it comes to medications, China’s control over the supply chain creates a situation where the Communist dictatorship can cut our throats and potentially execute a direct bioweapon attack.